4.34
3.13%
-0.14
OmniAb Inc stock is currently priced at $4.34, with a 24-hour trading volume of 528.54K.
It has seen a -3.13% decreased in the last 24 hours and a -2.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.51 pivot point. If it approaches the $4.32 support level, significant changes may occur.
Previous Close:
$4.48
Open:
$4.5
24h Volume:
528.54K
Market Cap:
$510.45M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-27.21
EPS:
-0.1595
Net Cash Flow:
$703.00K
1W Performance:
-1.14%
1M Performance:
-2.25%
6M Performance:
-1.14%
1Y Performance:
+0.46%
OmniAb Inc Stock (OABI) Company Profile
Name
OmniAb Inc
Sector
Industry
Phone
510 250 7800
Address
5980 Horton Street, Suite 600, EmeryVille
OmniAb Inc Stock (OABI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
Apr-21-23 | Initiated | The Benchmark Company | Buy |
Apr-13-23 | Initiated | Craig Hallum | Buy |
Feb-22-23 | Initiated | Cowen | Outperform |
Feb-13-23 | Initiated | H.C. Wainwright | Buy |
Dec-20-22 | Initiated | Truist | Buy |
Dec-16-22 | Initiated | Credit Suisse | Outperform |
Nov-29-22 | Initiated | SVB Leerink | Outperform |
Nov-28-22 | Initiated | Stifel | Buy |
View All
OmniAb Inc Stock (OABI) Latest News
There is no doubt that OmniAb Inc (OABI) ticks all the boxes. – Sete News - SETE News
SETE News
Insider Spends US$1.1m Buying More Shares In OmniAb - Simply Wall St
Simply Wall St
OmniAb Inc [OABI] Records 200-Day SMA of $5.22 – Knox Daily - Knox Daily
Knox Daily
Swiss National Bank Cuts Stock Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
Defense World
OmniAb (NASDAQ:OABI) Shares Gap Up After Insider Buying Activity - Defense World
Defense World
OmniAb (NASDAQ:OABI) Shares Gap Up on Insider Buying Activity - MarketBeat
MarketBeat
OmniAb Inc Stock (OABI) Financials Data
OmniAb Inc (OABI) Revenue 2024
OABI reported a revenue (TTM) of $34.16 million for the quarter ending December 31, 2023, a -42.17% decline year-over-year.
OmniAb Inc (OABI) Net Income 2024
OABI net income (TTM) was -$50.62 million for the quarter ending December 31, 2023, a -126.65% decrease year-over-year.
OmniAb Inc (OABI) Cash Flow 2024
OABI recorded a free cash flow (TTM) of $703.00 thousand for the quarter ending December 31, 2023, a +103.39% increase year-over-year.
OmniAb Inc (OABI) Earnings per Share 2024
OABI earnings per share (TTM) was -$0.508 for the quarter ending December 31, 2023, a -176.24% decline year-over-year.
About OmniAb Inc
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Cap:
|
Volume (24h):